PVLA insider transaction filings
PALVELLA THERAPEUTICS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen PVLA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 22 legs across 5 filings by 3 insiders — 40,719 shares, $6,168,192 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 6,520 shares @ $150.62 ($982,035) by JENKINS GEORGE M, filed 2026-09-15.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| JENKINS GEORGE M — Director | 1 | — | 9 legs · 27,500 sh · $4,167,146 | — |
| Goin Kathleen — Chief Operating Officer | 3 | — | 12 legs · 12,906 sh · $1,951,905 | 12 |
| KIRITSY CHRISTOPHER P — Director | 1 | — | 1 leg · 313 sh · $49,141 | 2 |
| Pauls Matthew — Director | 1 | — | — | 1 |
Recent Form 4 filings — PALVELLA THERAPEUTICS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 1,659 @ $151.16 · Sale (S): 989 @ $152.36 · Sale (S): 1,654 @ $153.24 · Option exercise (M): 2,154 (derivative) @ $0 · +1 more | EDGAR |
| 2026-09-15 | 4 | JENKINS GEORGE M — Director | Sale (S): 6,520 @ $150.62 · Sale (S): 4,577 @ $151.72 · Sale (S): 1,274 @ $153.06 · Sale (S): 5,632 @ $151.46 · Sale (S): 6,160 @ $152.12 · Sale (S): 1,560 @ $153.10 · +3 more | EDGAR |
| 2026-09-04 | 4 | KIRITSY CHRISTOPHER P — Director | Option exercise (M): 313 @ $127.20 · Sale (S): 313 @ $157 · Option exercise (M): 313 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 1,500 @ $151.39 · Sale (S): 1,998 @ $151.80 · Sale (S): 400 @ $153.00 · Sale (S): 102 @ $155.59 · +3 more | EDGAR |
| 2026-07-17 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 522 @ $147.14 · Sale (S): 840 @ $148.40 · Sale (S): 1,029 @ $149.27 · Sale (S): 1,911 @ $150.25 · +2 more | EDGAR |
| 2026-07-01 | 4 | Pauls Matthew — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 2,390 @ $110.26 · Sale (S): 1,887 @ $111.31 · Sale (S): 25 @ $112.23 · Option exercise (M): 2,154 (derivative) @ $0 · +1 more | EDGAR |
| 2026-06-16 | 4 | Korenberg Matthew E — CFO, Treasurer | Option exercise (M): 1,000 @ $13.60 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Doux John — Director | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Wessel Tadd S. — Director | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Davis Todd C — Director | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | JENKINS GEORGE M — Director | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | KIRITSY CHRISTOPHER P — Director | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | HERON ELAINE J — Director | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 3,363 @ $110.35 · Sale (S): 891 @ $111.30 · Sale (S): 48 @ $111.89 · Option exercise (M): 2,154 (derivative) @ $0 · +1 more | EDGAR |
| 2026-04-17 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 1,502 @ $125.96 · Sale (S): 1,500 @ $127.13 · Sale (S): 561 @ $128.23 · Sale (S): 639 @ $129.17 · +3 more | EDGAR |
| 2026-04-15 | 4 | Doux John — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | JENKINS GEORGE M — Director | Purchase (P): 445 @ $112.30 | EDGAR |
| 2026-03-20 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 2,268 @ $117.56 · Sale (S): 1,730 @ $118.37 · Sale (S): 304 @ $119.08 · Option exercise (M): 2,154 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-02 | 4 | JENKINS GEORGE M — Director | Purchase (P): 4,000 @ $125 | EDGAR |
| 2026-03-02 | 4 | HERON ELAINE J — Director | Purchase (P): 2,400 @ $125 | EDGAR |
| 2026-02-20 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 3,026 @ $79.16 · Sale (S): 1,276 @ $79.97 · Option exercise (M): 2,154 (derivative) @ $0 · Option exercise (M): 2,148 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Martini Jeffrey S — Chief Scientific Officer | Grant/award (A): 64,318 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Kline Ashley Hartmann — Chief Commercial Officer | Grant/award (A): 38,517 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Kaupinen Wes — President and CEO, Director, 10% owner | Grant/award (A): 124,603 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Korenberg Matthew E — CFO, Treasurer | Grant/award (A): 44,123 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Goin Kathleen — Chief Operating Officer | Grant/award (A): 48,956 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 553 @ $95.49 · Sale (S): 3,749 @ $97.94 · Option exercise (M): 2,154 (derivative) @ $0 · Option exercise (M): 2,148 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 4,302 @ $96.47 · Option exercise (M): 2,154 (derivative) @ $0 · Option exercise (M): 2,148 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Goin Kathleen — Chief Operating Officer | Option exercise (M): 2,154 @ $7.14 · Option exercise (M): 2,148 @ $9.08 · Sale (S): 1,500 @ $85.72 · Sale (S): 2,802 @ $86.51 · Option exercise (M): 2,154 (derivative) @ $0 · Option exercise (M): 2,148 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Wessel Tadd S. — Director | Grant/award (A): 12,350 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Davis Todd C — Director | Grant/award (A): 12,350 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | JENKINS GEORGE M — Director | Grant/award (A): 12,350 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | KIRITSY CHRISTOPHER P — Director | Grant/award (A): 12,350 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | HERON ELAINE J — Director | Grant/award (A): 12,350 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Kline Ashley Hartmann — Chief Commercial Officer | Grant/award (A): 17,436 (derivative) @ $0 · Grant/award (A): 111,496 (derivative) @ $0 | EDGAR |
| 2025-04-10 | 4 | JENKINS GEORGE M — Director | Purchase (P): 2,500 @ $20.13 · Purchase (P): 2,490 @ $20.27 | EDGAR |
| 2025-02-10 | 4/A | Kaupinen Wes — President and CEO, Director | Grant/award (A): 243,831 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4/A | Martini Jeffrey S — Chief Scientific Officer | Grant/award (A): 5,373 (derivative) @ $0 · Grant/award (A): 123,559 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4/A | Goin Kathleen — Chief Operating Officer | Grant/award (A): 5,373 (derivative) @ $0 · Grant/award (A): 123,559 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4/A | Korenberg Matthew E — CFO and Treasurer | Grant/award (A): 5,373 (derivative) @ $0 · Grant/award (A): 123,559 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | PALVELLA THERAPEUTICS, INC. — Chief Scientific Officer | Grant/award (A): 5,373 (derivative) @ $0 · Grant/award (A): 123,559 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | PALVELLA THERAPEUTICS, INC. — CFO and Treasurer | Grant/award (A): 5,373 (derivative) @ $0 · Grant/award (A): 123,559 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | PALVELLA THERAPEUTICS, INC. — President and CEO, Director | Grant/award (A): 243,831 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | PALVELLA THERAPEUTICS, INC. — Chief Operating Officer | Grant/award (A): 5,373 (derivative) @ $0 · Grant/award (A): 123,559 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | JENKINS GEORGE M — Director | Purchase (P): 4,000 @ $12.93 | EDGAR |
| 2024-12-17 | 4 | JENKINS GEORGE M — Director | Grant/award (A): 24,700 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | KIRITSY CHRISTOPHER P — Director | Grant/award (A): 24,700 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | HERON ELAINE J — Director | Grant/award (A): 24,700 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC/IL LAMPERT MARK N | Other (J): 234,323 · Other (J): 174,958 · Other (J): 29,648 | EDGAR |
Recent 8-K events — PALVELLA THERAPEUTICS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PVLA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →